- $10.8 BnWorld market, 2023
- $19.3 BnProjected, 2033
- 6%Growth a year (CAGR)
- 215Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$4.5 Bn
4% a year · 42% of the world -
2
China
$868 Mn
7.5% a year · 8% of the world -
3
Canada
$864 Mn
6% a year · 8% of the world -
4
Japan
$671 Mn
6.5% a year · 6.2% of the world -
5
Germany
$395 Mn
4.2% a year · 3.7% of the world -
6
France
$297 Mn
5% a year · 2.8% of the world -
7
UK
$281 Mn
4% a year · 2.6% of the world -
8
Brazil
$270 Mn
7% a year · 2.5% of the world -
9
Italy
$259 Mn
5.5% a year · 2.4% of the world -
10
Ecuador
$216 Mn
6.6% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)
Australia
Mexico
EgyptDiabetic Retinopathy Drugs by country and region
Spain
India
Saudi Arabia
South Africa
UAE
Philippines
Malaysia
Hong Kong
Singapore
Thailand
Kenya
New Zealand
Russia"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 15,472 papers since 2021
- The association of physical activity and sedentary behaviour with the development and progression of microvascular complications in type 1 and type 2 diabetes: A systematic review of cohort studies. Diabetes research and clinical practice, 2026
- Association of Fenofibrate Add-on Therapy with Postoperative Diabetic Retinal Outcomes After Cataract Surgery in Patients with Type 2 Diabetes Mellitus. Retina (Philadelphia, Pa.), 2026
- Macular Choroidal Thickness in Unilateral Idiopathic Epiretinal Membrane: A Fellow-Eye-Controlled Cross-Sectional Study. Clinical ophthalmology (Auckland, N.Z.), 2026
- The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability. Journal of vitreoretinal diseases, 2026
- The pathological role of chemokines and chemokine receptors in diabetic vascular disease. Cytokine, 2026
Patients: Diabetes (adults)
| Place | Value | Year |
|---|---|---|
| World | 14.1 | 2022 |
| Australia | 8.1 | 2022 |
| Brazil | 12.9 | 2022 |
| Canada | 6.8 | 2022 |
| China | 11.2 | 2022 |
| Ecuador | 12.7 | 2022 |
| Egypt | 27.8 | 2022 |
| France | 2.7 | 2022 |
| Germany | 6.6 | 2022 |
| India | 22.6 | 2022 |
| Italy | 7.2 | 2022 |
| Japan | 6.4 | 2022 |
| Kenya | 5.6 | 2022 |
| Malaysia | 26.7 | 2022 |
| Mexico | 14.3 | 2022 |
| New Zealand | 9.0 | 2022 |
| Philippines | 13.2 | 2022 |
| Russia | 8.1 | 2022 |
| Saudi Arabia | 20.8 | 2022 |
| Singapore | 13.1 | 2022 |
| South Africa | 13.9 | 2022 |
| Spain | 3.6 | 2022 |
| Thailand | 12.3 | 2022 |
| UAE | 26.1 | 2022 |
| UK | 8.8 | 2022 |
| US | 12.5 | 2022 |
Compare Diabetic Retinopathy Drugs side by side
Key companies in Diabetic Retinopathy Drugs
Regeneron Pharmaceuticals
Novartis AG
Allergan (AbbVie Inc.)
Genentech
Bayer AG
Roche Holding AG.
AbbVie Inc.
Alimera Sciences
Ampio Pharmaceuticals.
Quick answers
How big is the Diabetic Retinopathy Drugs market?
The world Diabetic Retinopathy Drugs market was worth about $10.8 Bn in 2023 and is projected to reach $19.3 Bn by 2033, growing 6% a year (CAGR).
Which country has the largest Diabetic Retinopathy Drugs market?
The US is the largest of the 24 countries we cover, at $4.5 Bn in 2023. India grows fastest, at 9% a year.
How many clinical trials are running in Diabetic Retinopathy Drugs?
ClinicalTrials.gov lists 215 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Diabetic Retinopathy Drugs?
PubMed lists about 15,472 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Patients: WHO Global Health Observatory. Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.